AJP - Heart and Circulatory Physiology, Vol 256, Issue 4 1236-H1246, Copyright © 1989 by American Physiological Society

ARTICLES

Release of platelet-activating factor from ischemic-reperfused rabbit heart

G. Montrucchio, G. Alloatti, C. Tetta, R. De Luca, R. N. Saunders, G. Emanuelli and G. Camussi
Clinica Medica Generale III, Ospedale S. Luigi Gonzaga Torino, Italy.

This study shows that platelet-activating factor (PAF) is released in significant amounts (10.9 +/- 12.8 ng/min) during the initial reperfusion of the ischemic-isolated rabbit heart. When reperfusion was performed in the presence of autologous rabbit platelets, the electrical and mechanical alterations characteristic of this phase were significantly worsened. These alterations were antagonized by pretreatment of rabbit platelets with a PAF receptor antagonist (SDZ 63-675), suggesting a contribution of PAF released during reperfusion in the cardiac dysfunction. To discriminate whether the effect of PAF was platelet dependent, infusion of PAF (10-40 ng) was performed in nonischemic rabbit hearts perfused with or without autologous platelets. Although the effect of PAF per se was minimal, in the presence of platelets PAF induced a biphasic effect characterized by a transient positive inotropism followed by a dose-dependent decrease in coronary flow, negative inotropism, reduction of action potential duration, and conduction arrhythmias. These effects were abolished by pretreatment of platelets with SDZ 63-675, suggesting a PAF receptor-mediated platelet activation. In addition, a relative contribution of histamine, thromboxanes, and leukotrienes released from activated platelets was inferred by experiments performed with pyrilamine and cimetidine, imidazole, and FPL 55712, respectively.

This article has been cited by other articles:

				C. Penna, G. Alloatti, S. Cappello, D. Gattullo, G. Berta, B. Mognetti, G. Losano, and P. Pagliaro Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2512 - H2520. [Abstract] [Full Text] [PDF]

				G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF]

				M. Riera, J. Torras, I. Herrero, J. Valles, M. Paubert-Braquet, J. M. Cruzado, J. Alsina, and J. M. Grinyo Neutrophils Accentuate Renal Cold Ischemia-Reperfusion Injury. Dose-Dependent Protective Effect of a Platelet-Activating Factor Receptor Antagonist J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 786 - 794. [Abstract] [Full Text]

				P. R. Hansen Role of Neutrophils in Myocardial Ischemia and Reperfusion Circulation, March 15, 1995; 91(6): 1872 - 1885. [Abstract] [Full Text]

				Y. Sawa, J. Schaper, M. Roth, K. Nagasawa, G. Ballagi, N. Bleese, and W. Schaper Platelet-activating factor plays an important role in reperfusion injury in myocardiumEfficacy of platelet-activating factor receptor antagonist (CV-3988) as compared with leukocyte-depleted reperfusion J. Thorac. Cardiovasc. Surg., November 1, 1994; 108(5): 953 - 959. [Abstract] [Full Text]